Haihai Jiang, Yanru Zhou, Xiaofang Zou, Xiaohui Hu, Jie Wang, Pei Zeng, Wenwen Li, Xiangyi Zeng, Jin Zhang, Jian Li
SARS-CoV-2 continues to pose a threat to public health. Main protease (Mpro ) is one of the most lucrative drug targets for developing specific antivirals against SARS-CoV-2 infection. By targeting Mpro , peptidomimetic nirmatrelvir is able to inhibit viral replication of SARS-CoV-2 and reduce the risk for progression to severe COVID-19. However, multiple mutations in the gene encoding Mpro of emerging SARS-CoV-2 variants raise a concern of drug resistance. In the present study, we expressed 16 previously reported SARS-CoV-2 Mpro mutants (G15S, T25I, T45I, S46F, S46P, D48N, M49I, L50F, L89F, K90R, P132H, N142S, V186F, R188K, T190I, and A191V)...
May 24, 2023: Biochemistry